Triple-Negative Breast Cancer

A study assessing the efficacy of pembrolizumab met a key secondary endpoint of extending OS, in combination with chemotherapy, among patients with high-risk early-stage triple-negative breast cancer, according to the agent’s manufacturer.

Paolo Tarantino, MD, discusses the role of collaborative management of patients with metastatic breast cancer.

SAN ANTONIO — Use of pembrolizumab with neoadjuvant chemotherapy and as monotherapy in the adjuvant setting provided a durable EFS benefit for patients with early-stage triple-negative breast cancer, according to study results.

SAN ANTONIO — Tinengotinib exhibited activity among heavily pretreated patients with hormone receptor-positive, HER2-negative breast cancer or those with triple-negative disease, according to study results.

Preliminary results of a phase 1 trial for a novel vaccine that could eventually prevent triple-negative breast cancer exceeded expectations, based on data presented at San Antonio Breast Cancer Symposium.

Older patients undergoing immunotherapy for breast cancer experienced similar rates of immune-related adverse events as younger patients, according to a presenter at San Antonio Breast Cancer Symposium.

Pembrolizumab plus olaparib did not improve outcomes among patients with locally recurrent inoperable or metastatic triple-negative breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — The addition of atezolizumab to adjuvant chemotherapy “is very unlikely” to improve DFS for women with stage II or stage III triple-negative breast cancer, according to data presented at San Antonio Breast Cancer Symposium.

Lali Medina-Kauwe, PhD, has been named the inaugural Carol Moss Foundation chair in medical discovery at Cedars-Sinai.

CHICAGO — The addition of toripalimab to first-line nab-paclitaxel significantly prolonged PFS among patients with PD-L1-positive metastatic or recurrent triple-negative breast cancer, according to results of a phase 3 trial.